

Alison Taunton-Rigby, PhD, OBE

President and CEO
RiboNovix, Inc.



Alison Taunton-Rigby, PhD, OBE, has been a senior executive in the biotechnology industry for over 25 years. She is Founder, President and Chief Executive Officer of RiboNovix, Inc., an early stage biotechnology company developing novel anti-infectives that are less susceptible to drug resistance. RiboNovix has laboratories in Lexington Massachusetts.

Dr. Taunton-Rigby was President and Chief Executive Officer of Aquila Biopharmaceuticals, Inc., a public life sciences company that was merged in late 2000 with Antigenics Inc. She was also President and Chief Executive Officer of Cambridge Biotech Corporation, where she led the turn-around, re-structuring and emergence from bankruptcy. In addition, she has served as President and Chief Executive Officer of Mitotix Inc., now merged with GPC Biotech. Previous to this position, she was Senior Vice President, Biotherapeutics, at Genzyme Corporation, where she had overall responsibility for Genzyme's biotherapeutics division. Dr. Taunton-Rigby has also served in senior management positions at Vivotech Inc., Biogen, Inc. and Collaborative Research, Inc. (now Genome Therapeutics Inc.).

Dr. Taunton-Rigby received her doctorate in chemistry from the University of Bristol in England, and is a graduate of the Advanced Management Program of the Harvard Business School. She is a Director of RiverSource Funds (formerly American Express Funds), Healthways, Inc., Abt Associates, Inc., Idera Pharmaceuticals, Inc., the Massachusetts Biotechnology Council, the Massachusetts Women's Forum, a trustee of The Children's Hospital Boston, and a member of the Board of Associates of the Whitehead Institute for Biomedical Research, and Bentley College Center for Business Ethics. In 2002 she was awarded the OBE (Officer of the Order of the British Empire) by Queen Elizabeth II for her work as a leader in the research, development and promotion of biotechnology.